General
Pfizer fined £84.2m by UK’s competition regulator for overcharging NHS
 

Pfizer fined £84.2m by UK’s competition regulator for overcharging NHS

Shared by:

 
Pfizer and Flynn Pharma were fined by UK’s Competition and Markets Authority for “excessive and unfair prices” for a generic epilepsy drug. The fine issued to Pfizer is one of the largest in the country’s history.
 
today.mims.com
 
12 Dec 2016 - General
 
Priscilla Mae Gobuyan Over pricing is burden to patient and governments also. Even innovator companies enjoyed 5 years of market exclusivity, it is unfair to see raised price. It is an aler...
 (Total 44 words)
Well the fine is only enough for the overpricing of the medications. It is impossible to have that hike on prices in just a short period of time provided that there were no new innovations and investments on the said drugs. I pity those who have paid...
 (Total 61 words)
Pfizer has been fined a record £84.2m by the UK’s competition regulator for overcharging the NHS 2600% for an anti-epilepsy drug, phenytoin sodium capsules. The Competition and Markets Authority (CMA) also fined Flynn Pharma, the drug’s distribu...
 (Total 43 words)